Bright Minds Biosciences (DRUG) Accumulated Expenses (2020 - 2026)

Bright Minds Biosciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $347375.4 for Q1 2026.

• Quarterly Accumulated Expenses rose 164.64% year-over-year to $347375.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $347375.4 (up 164.64% YoY) and the FY2025 annual result came in at $392781.8, up 1183.36% from the prior year.
• Accumulated Expenses was $347375.4 for Q1 2026 at Bright Minds Biosciences, up from $157705.2 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $645275.0 in Q2 2023 and bottomed at $30605.7 in Q3 2024.
• A 5-year average of $249758.9 and a median of $177850.4 in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 78.45% — and 2025, when it soared 1183.36%.
• Bright Minds Biosciences' Accumulated Expenses stood at $386005.8 in 2022, then slumped by 78.45% to $83171.5 in 2023, then dropped by 16.29% to $69625.6 in 2024, then surged by 126.5% to $157705.2 in 2025, then jumped by 120.27% to $347375.4 in 2026.
• Business Quant data shows DRUG's Accumulated Expenses at $347375.4 in Q1 2026, $157705.2 in Q4 2025, and $392781.8 in Q3 2025.